
Mirai Bio to Reveal Two Next-Gen Targeted Nucleic Acid Delivery Programs Beyond the Liver at ASGCT 2026
Mirai Bio to Debut Two Next-Generation Programs for Extrahepatic Targeted Nucleic Acid Delivery at the ASGCT 2026 Annual Meeting Mirai Bio, a company focused on enabling the next generation of nucleic acid therapeutics through advanced delivery technologies, has announced its…












